oxford cancer analytics ltd
oxford cancer analytics ltd Company Information
Company Number
12437885
Next Accounts
Sep 2025
Industry
Research and experimental development on biotechnology
Other human health activities
Shareholders
jian rui liu
andreas halner
View AllGroup Structure
View All
Contact
Registered Address
bioescalator innovation building, building 696, old road campus, r, oxford, OX3 7FZ
Website
-oxford cancer analytics ltd Estimated Valuation
Pomanda estimates the enterprise value of OXFORD CANCER ANALYTICS LTD at £1m based on a Turnover of £1m and 1.03x industry multiple (adjusted for size and gross margin).
oxford cancer analytics ltd Estimated Valuation
Pomanda estimates the enterprise value of OXFORD CANCER ANALYTICS LTD at £0 based on an EBITDA of £-1.9m and a 4.81x industry multiple (adjusted for size and gross margin).
oxford cancer analytics ltd Estimated Valuation
Pomanda estimates the enterprise value of OXFORD CANCER ANALYTICS LTD at £4.3m based on Net Assets of £2m and 2.16x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Oxford Cancer Analytics Ltd Overview
Oxford Cancer Analytics Ltd is a live company located in oxford, OX3 7FZ with a Companies House number of 12437885. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in February 2020, it's largest shareholder is jian rui liu with a 34.1% stake. Oxford Cancer Analytics Ltd is a young, small sized company, Pomanda has estimated its turnover at £1m with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Oxford Cancer Analytics Ltd Health Check
Pomanda's financial health check has awarded Oxford Cancer Analytics Ltd a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 3 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
3 Weak
Size
annual sales of £815.4k, make it smaller than the average company (£1.9m)
- Oxford Cancer Analytics Ltd
£1.9m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Oxford Cancer Analytics Ltd
- - Industry AVG
Production
with a gross margin of 46.1%, this company has a comparable cost of product (46.1%)
- Oxford Cancer Analytics Ltd
46.1% - Industry AVG
Profitability
an operating margin of -119.1% make it less profitable than the average company (3.3%)
- Oxford Cancer Analytics Ltd
3.3% - Industry AVG
Employees
with 9 employees, this is below the industry average (30)
9 - Oxford Cancer Analytics Ltd
30 - Industry AVG
Pay Structure
on an average salary of £49.4k, the company has an equivalent pay structure (£49.4k)
- Oxford Cancer Analytics Ltd
£49.4k - Industry AVG
Efficiency
resulting in sales per employee of £90.6k, this is equally as efficient (£90.6k)
- Oxford Cancer Analytics Ltd
£90.6k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Oxford Cancer Analytics Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Oxford Cancer Analytics Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Oxford Cancer Analytics Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 8277 weeks, this is more cash available to meet short term requirements (76 weeks)
8277 weeks - Oxford Cancer Analytics Ltd
76 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.6%, this is a lower level of debt than the average (38.1%)
0.6% - Oxford Cancer Analytics Ltd
38.1% - Industry AVG
OXFORD CANCER ANALYTICS LTD financials
Oxford Cancer Analytics Ltd's latest turnover from December 2023 is estimated at £1 million and the company has net assets of £2 million. According to their latest financial statements, Oxford Cancer Analytics Ltd has 11 employees and maintains cash reserves of £751.7 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Feb 2023 | Feb 2022 | Feb 2021 | |
|---|---|---|---|---|
| Turnover | ||||
| Other Income Or Grants | ||||
| Cost Of Sales | ||||
| Gross Profit | ||||
| Admin Expenses | ||||
| Operating Profit | ||||
| Interest Payable | ||||
| Interest Receivable | ||||
| Pre-Tax Profit | ||||
| Tax | ||||
| Profit After Tax | ||||
| Dividends Paid | ||||
| Retained Profit | ||||
| Employee Costs | ||||
| Number Of Employees | 11 | 9 | 7 | |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Feb 2023 | Feb 2022 | Feb 2021 | |
|---|---|---|---|---|
| Tangible Assets | 278,234 | 141,074 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 278,234 | 141,074 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 |
| Misc Debtors | 1,395 | 1,901 | 100 | 100 |
| Cash | 751,725 | 2,969,557 | 996,017 | 38,933 |
| misc current assets | 991,583 | 0 | 0 | 0 |
| total current assets | 1,744,703 | 2,971,458 | 996,117 | 39,033 |
| total assets | 2,022,937 | 3,112,532 | 996,117 | 39,033 |
| Bank overdraft | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 12 | 12 | 12 | 12 |
| other short term finances | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 |
| other current liabilities | 14,673 | 18,644 | 38,216 | 40,000 |
| total current liabilities | 14,685 | 18,656 | 38,228 | 40,012 |
| loans | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 |
| total liabilities | 14,685 | 18,656 | 38,228 | 40,012 |
| net assets | 2,008,252 | 3,093,876 | 957,889 | -979 |
| total shareholders funds | 2,008,252 | 3,093,876 | 957,889 | -979 |
| Dec 2023 | Feb 2023 | Feb 2022 | Feb 2021 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Operating Profit | ||||
| Depreciation | 78,648 | 8,047 | 0 | 0 |
| Amortisation | 0 | 0 | 0 | 0 |
| Tax | ||||
| Stock | 0 | 0 | 0 | 0 |
| Debtors | 1,295 | 1,801 | 0 | 100 |
| Creditors | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | -23,543 | -19,572 | -1,784 | 40,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||
| Investing Activities | ||||
| capital expenditure | ||||
| Change in Investments | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||
| Financing Activities | ||||
| Bank loans | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 12 |
| Other Short Term Loans | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 |
| share issue | ||||
| interest | ||||
| cash flow from financing | ||||
| cash and cash equivalents | ||||
| cash | -244,292 | 1,973,540 | 957,084 | 38,933 |
| overdraft | 0 | 0 | 0 | 0 |
| change in cash | -244,292 | 1,973,540 | 957,084 | 38,933 |
oxford cancer analytics ltd Credit Report and Business Information
Oxford Cancer Analytics Ltd Competitor Analysis
Perform a competitor analysis for oxford cancer analytics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in OX3 area or any other competitors across 12 key performance metrics.
oxford cancer analytics ltd Ownership
OXFORD CANCER ANALYTICS LTD group structure
Oxford Cancer Analytics Ltd has no subsidiary companies.
Ultimate parent company
OXFORD CANCER ANALYTICS LTD
12437885
oxford cancer analytics ltd directors
Oxford Cancer Analytics Ltd currently has 6 directors. The longest serving directors include Mr Jian Liu (Feb 2020) and Mr Andreas Halner (Feb 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Jian Liu | England | 32 years | Feb 2020 | - | Director |
| Mr Andreas Halner | England | 28 years | Feb 2020 | - | Director |
| Mr Marcus East | United States | 52 years | Jan 2021 | - | Director |
| Mr Bradley Wilson | England | 77 years | Jun 2021 | - | Director |
| Ms Gemma Sturt | Spain | 27 years | Nov 2024 | - | Director |
| Ms Annie Theriault | Canada | 47 years | Nov 2024 | - | Director |
P&L
December 2023turnover
1m
+67%
operating profit
-2m
0%
gross margin
45.3%
+6.17%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
2m
+1.1%
total assets
2m
+1.03%
cash
751.7k
-0.25%
net assets
Total assets minus all liabilities
Similar Companies
oxford cancer analytics ltd company details
company number
12437885
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
86900 - Other human health activities
incorporation date
February 2020
age
5
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
-
address
bioescalator innovation building, building 696, old road campus, r, oxford, OX3 7FZ
Bank
-
Legal Advisor
-
oxford cancer analytics ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to oxford cancer analytics ltd.
oxford cancer analytics ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for OXFORD CANCER ANALYTICS LTD. This can take several minutes, an email will notify you when this has completed.
oxford cancer analytics ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
